Cargando…
10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
OBJECTIVES: The German Pharmaceutical Market Restructuring Act (AMNOG, 2011) is a two-stage process to regulate the price of new pharmaceuticals in which price negotiations are conducted based on evidence-based medical benefit assessments using data from prior clinical trials. Although the act does...
Autores principales: | Büssgen, Melanie, Stargardt, Tom |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227403/ https://www.ncbi.nlm.nih.gov/pubmed/37249741 http://dx.doi.org/10.1007/s40258-023-00815-7 |
Ejemplares similares
-
Does health technology assessment compromise access to pharmaceuticals?
por: Büssgen, Melanie, et al.
Publicado: (2022) -
Does health technology assessment compromise access to pharmaceuticals?
por: Büssgen, Melanie, et al.
Publicado: (2023) -
Changes in launch delay and availability of pharmaceuticals in 30 European markets over the past two decades
por: Büssgen, Melanie, et al.
Publicado: (2022) -
How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?
por: Dintsios, Charalabos-Markos, et al.
Publicado: (2021) -
Implementation of AMNOG: An industry perspective
por: Leverkus, Friedhelm, et al.
Publicado: (2015)